Mark Trusheim
Strategic Director, NEWDIGS, Tufts Medical Center
Mark Trusheim is Strategic Director, NEWDIGS at Tufts Medical Center where he also co-leads the Financing and reimbursement of Cures in the US (FoCUS) Project.
Mark’s research focuses on the economics of biomedical innovation, especially precision financing for patient access, precision medicine, adaptive pathways, platform trials, biosimilars, and digital health advances. Mark held appointments for 18 years at MIT Sloan in Applied Economics and has served as a Special Government Employee for the FDA’s Office of the Commissioner.
Mark is also President of Co-Bio Consulting, LLC. His career has spanned policy as the President of the Massachusetts Biotechnology Council, diagnostics as founder of Cantata Labs, genomics as President of Cereon Genomics, eHealth as Vice President of Monsanto Health Solutions, managed care marketing at Searle Pharmaceuticals, and big data at Kenan Systems.
He holds degrees in Chemistry from Stanford University and Management from MIT.